Perceptive Advisors LLC Stake in Nxstage Medical INC (NXTM) Has Cut by $6.57 Million

November 21, 2017 - By Michael Collier

Investors sentiment increased to 1.14 in 2017 Q2. Its up 0.10, from 1.04 in 2017Q1. It is positive, as 24 investors sold NXTM shares while 47 reduced holdings. 28 funds opened positions while 53 raised stakes. 58.75 million shares or 4.24% less from 61.35 million shares in 2017Q1 were reported. 266,900 were reported by Point72 Asset Mngmt L P. Illinois-based Citadel Advsr Limited Com has invested 0% in NxStage Medical, Inc. (NASDAQ:NXTM). Tiverton Asset Mngmt Ltd Liability Corp reported 110,742 shares. Ny State Common Retirement Fund reported 68,600 shares. Employees Retirement Of Texas holds 0.01% or 43,000 shares. Great West Life Assurance Can holds 0% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM) for 8,228 shares. Perceptive Advsrs owns 1.56M shares. Sterling Cap Ltd Liability Corporation invested in 64,574 shares. Jpmorgan Chase And holds 0% or 780 shares. Birchview Capital Lp reported 34,200 shares or 0.45% of all its holdings. Point72 Asia (Hong Kong) Ltd owns 165 shares. D E Shaw & Inc has invested 0.01% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Rhenman & Prns Asset Ab holds 213,901 shares or 0.77% of its portfolio. Citigroup stated it has 0% in NxStage Medical, Inc. (NASDAQ:NXTM). Comml Bank Of Mellon owns 587,996 shares for 0% of their portfolio.

Since May 22, 2017, it had 0 insider buys, and 2 insider sales for $134,068 activity. Shares for $91,848 were sold by TOWSE MATTHEW W on Monday, May 22. 2,250 NxStage Medical, Inc. (NASDAQ:NXTM) shares with value of $53,078 were sold by Turk Joseph E Jr.

Joseph Edelman decreased its stake in Nxstage Medical Inc (NXTM) by 14.45% based on its latest 2017Q2 regulatory filing with the SEC. Perceptive Advisors Llc sold 262,666 shares as the company’s stock declined 27.12% while stock markets rallied. The hedge fund run by Joseph Edelman held 1.56M shares of the health care company at the end of 2017Q2, valued at $39.00 million, down from 1.82 million at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Nxstage Medical Inc for a number of months, seems to be less bullish one the $1.74 billion market cap company. The stock rose 1.39% or $0.36 reaching $26.26. About 40,386 shares traded. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 21.18% since November 21, 2016 and is uptrending. It has outperformed by 4.48% the S&P500.

Perceptive Advisors Llc, which manages about $2.09B and $1.99 billion US Long portfolio, upped its stake in Humana Inc (NYSE:HUM) by 50,593 shares to 78,093 shares, valued at $18.79 million in 2017Q2, according to the filing. It also increased its holding in Selecta Biosciences Inc by 655,450 shares in the quarter, for a total of 797,325 shares, and has risen its stake in Quotient Ltd (NASDAQ:QTNT).

More recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Prnewswire.com which released: “Breakfast Technical Briefing on Medical Equipment Stocks — Hologic, Nxstage …” on November 16, 2017. Also Nasdaq.com published the news titled: “NxStage Medical Stockholders Ok Merger Agreement With Fresenius Medical Care” on October 30, 2017. Prnewswire.com‘s news article titled: “NxStage Announces Stockholder Approval Of Merger Agreement With Fresenius …” with publication date: October 27, 2017 was also an interesting one.

NxStage Medical, Inc. (NASDAQ:NXTM) Ratings Coverage

Among 9 analysts covering NxStage Medical (NASDAQ:NXTM), 2 have Buy rating, 1 Sell and 6 Hold. Therefore 22% are positive. NxStage Medical had 18 analyst reports since November 4, 2015 according to SRatingsIntel. BTIG Research maintained the stock with “Buy” rating in Tuesday, June 6 report. The firm has “Hold” rating given on Monday, August 7 by Craig Hallum. Jefferies maintained NxStage Medical, Inc. (NASDAQ:NXTM) on Tuesday, October 10 with “Hold” rating. As per Monday, August 7, the company rating was downgraded by Canaccord Genuity. As per Tuesday, June 28, the company rating was upgraded by Northland Capital. Northland Capital maintained NxStage Medical, Inc. (NASDAQ:NXTM) on Monday, August 7 with “Hold” rating. The rating was maintained by Canaccord Genuity with “Hold” on Monday, September 11. The stock has “Market Perform” rating by Leerink Swann on Tuesday, August 22. On Tuesday, August 8 the stock rating was downgraded by Jefferies to “Hold”. The company was downgraded on Friday, August 11 by BTIG Research.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.